The DOI matches its Crossref record; 83 of the 85 references it cites were found in a registry or an index.
Osteoprotegerin: Multiple partners for multiple functions
Abstract
Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation. However, there are additional ligands of OPG that confer various biological functions. OPG can promote cell survival, cell proliferation and facilitates migration by binding TNF-related apoptosis inducing ligand (TRAIL), glycosaminoglycans or proteoglycans. A large number of in vitro, pre-clinical and clinical studies provide evidences of OPG involvement in vascular, bone, immune and tumor biology. This review describes an overview of the different OPG ligands regulating its biological functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33–35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33–35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 2×
“The binding of OPG to RANKL prevents the interaction of RANKL for RANK expressed on the cell surface of osteoclast precursors, and thus inhibits the formation of osteoclasts (Boyle et al. 2003).”
BackgroundOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M. R., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J. M., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,722
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 2×
“These data are consistent with a randomized study showing that the prophylaxis with recombinant Factor VIII prevents joint damages in young haemophilic patients (Manco-Johnson et al. 2007), possibly through a decrease in osteoclastogenesis.”
ResultCellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S. D., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,183
Wong, B. R., Rho, J., Arron, J. R., Robinson, E. A., Orlinick, J. R., Chao, M. V., Kalachikov, S. M., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Bolton-Maggs, P., & Pasi, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13405-8 · Cited by 716
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Self-citationRegulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Collin‐Osdoby, P. (2004) · Circulation Research · doi:10.1161/01.res.0000149165.99974.12 · Cited by 474
Biological functions of tumor necrosis factor cytokines and their receptors
Pfeffer, K. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00022-4 · Cited by 412
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.
Price, P. A., June, H. H., Buckley, J. R., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1001.097102 · Cited by 376
Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells
Malyankar, U. M., Scatena, M., Suchland, K. L., Yun, T. J., Clark, E. A., & Giachelli, C. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000290200 · Cited by 348
Conformation and dynamics of heparin and heparan sulfate
Mulloy, B., & Forster, M. J. (2000) · Glycobiology · doi:10.1093/glycob/10.11.1147 · Cited by 325
GLYCOMICS APPROACH TO STRUCTURE-FUNCTION RELATIONSHIPS OF GLYCOSAMINOGLYCANS
Sasisekharan, R., Raman, R., & Prabhakar, V. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095745 · Cited by 296
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Holen, I., Croucher, P. I., Hamdy, F. C., & Eaton, C. L. (2002) · PubMed · Cited by 270
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.
Standal, T., Seidel, C., Hjertner, Ø., Plesner, T., Sanderson, R. D., Waage, A., Borset, M., & Sundan, A. (2002) · Blood · doi:10.1182/blood-2002-04-1190 · Cited by 244
Shipman, C. M., & Croucher, P. I. (2003) · PubMed · Cited by 242
Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure
Ueland, T., Yndestad, A., Øie, E., Florholmen, G., Halvorsen, B. L., Frøland, S. S., Simonsen, S., Christensen, G., Gullestad, L. L., & Aukrust, P. (2005) · Circulation · doi:10.1161/01.cir.0000165119.62099.14 · Cited by 227
Dumas, J. J., Kumar, R. A., McDonagh, T., Sullivan, F. J., Stahl, M., Somers, W. S., & Mosyak, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401659200 · Cited by 204
Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor
Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., & Higashio, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5117 · Cited by 200
Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. K., Mohaupt, M., Herring, S. W., & Clark, E. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1482 · Cited by 195
Lamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181
Self-citationRANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédiní, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 177
Self-citationZannettino, A. C. W., Holding, C. A., Diamond, P., Atkins, G. J., Kostakis, P., Farrugia, A., Gamble, J. R., To, L. B., Findlay, D. M., & Haynes, D. R. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20354 · Cited by 169
Neville-Webbe, H. L., Cross, N. A., Eaton, C. L., Nyambo, R., Evans, C. A., Coleman, R. E., & Holen, I. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000036900.48763.b3 · Cited by 141
Pritzker, L. B., Scatena, M., & Giachelli, C. M. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-01-0059 · Cited by 141
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Zauli, G., Corallini, F., Bossi, F., Fabio Fischetti, I., Durigutto, P., Celeghini, C., Tedesco, F., & Secchiero, P. (2007) · Blood · doi:10.1182/blood-2007-01-068395 · Cited by 133
Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease
Ziegler, S., Kudlacek, S., Luger, A., & Minar, E. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.01.042 · Cited by 123
Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand
Schneeweis, L. A., Willard, D., & Milla, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506366200 · Cited by 116
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahara, K., & Sanai, Y. (2007) · Bone · doi:10.1016/j.bone.2007.04.190 · Cited by 116
Mangan, S., Campenhout, A. V., Rush, C. M., & Golledge, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.07.017 · Cited by 116
Medial arterial calcification in diabetes and its relationship to neuropathy
Jeffcoate, W. J., Rasmussen, L. M., Hofbauer, L. C., & Game, F. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1521-6 · Cited by 113
Cross, S. S., Yang, Z., Brown, N. J., Balasubramanian, S. P., Evans, C. A., Woodward, J. K. L., Neville-Webbe, H. L., Down, J. M., Reed, M., Coleman, R. E., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21606 · Cited by 108
Cytokines and proteoglycans: an introductory overview
Mulloy, B., & Rider, C. C. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340409 · Cited by 107
Crystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin
Luan, X., Lu, Q., Jiang, Y., Zhang, S., Wang, Q., Yuan, H., Zhao, W., Wang, J., & Wang, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103387 · Cited by 104
Théoleyre, S., Tat, S. K., Vusio, P., Blanchard, F., Gallagher, J. T., Ricard‐Blum, S., Fortun, Y., Padrines, M., Rédiní, F., & Heymann, D. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.120 · Cited by 100
Self-citationFactor VIII-von Willebrand Factor Complex Inhibits Osteoclastogenesis and Controls Cell Survival
Baud’huin, M., Duplomb, L., Télétchéa, S., Charrier, C., Maillasson, M., Fouassier, M., & Heymann, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030312 · Cited by 93
Self-citationSyndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes
Mosheimer, B. A., Kaneider, N. C., Feistritzer, C., Djanani, A. M., Sturn, D. H., Patsch, J. R., & Wiedermann, C. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1895 · Cited by 91
Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function
McGonigle, J. S., Giachelli, C. M., & Scatena, M. (2008) · Angiogenesis · doi:10.1007/s10456-008-9127-z · Cited by 90
Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension
Lawrie, A., Waterman, E., Southwood, M. R., EVANS, D. B., Suntharalingam, J., Francis, S., Crossman, D. C., Croucher, P. I., Morrell, N. W., & Newman, C. M. H. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070395 · Cited by 89
Structural Basis of von Willebrand Factor Activation by the Snake Toxin Botrocetin
Fukuda, K., Doggett, T. A., Bankston, L. A., Crúz, M. A., Diacovo, T. G., & Liddington, R. (2002) · Structure · doi:10.1016/s0969-2126(02)00787-6 · Cited by 88
Crystal Structure of von Willebrand Factor A1 Domain Complexed with Snake Venom, Bitiscetin
Maita, N., Nishio, K., Nishimoto, E., Matsui, T., Shikamoto, Y., Morita, T., Sadler, J. E., & Mizuno, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305566200 · Cited by 86
Heath, D. J., Vanderkerken, K., Cheng, X., Gallagher, O., Prideaux, M., Murali, R., & Croucher, P. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1287 · Cited by 82
Characterization of the interaction between von Willebrand factor and osteoprotegerin
Shahbazi, S., Lenting, P. J., Fribourg, C., Terraube, V., Denis, C. V., & Christophe, O. D. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02681.x · Cited by 77
Chipoy, C., Berreur, M., Couillaud, S., Pradal, G., Vallette, F. M., Colombeix, C., Rédiní, F., Heymann, D., & Blanchard, F. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040817 · Cited by 75
Self-citationBenslimane-Ahmim, Z., Heymann, D., Dizier, B., Lokajczyk, A., Brion, R., Laurendeau, I., Bièche, I., Smadja, D. M., Galy–Fauroux, I., Colliec‐Jouault, S., et al. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04207.x · Cited by 66
Self-citationHuman Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL-Induced Apoptosis
Nyambo, R., Cross, N. A., Down, J. M., Holen, I., Bryden, G., Hamdy, F. C., & Eaton, C. L. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040703 · Cited by 65
Regulation of von Willebrand factor-platelet interactions
Pegon, J. N., Groot, E., de Groot, P. G., & Lenting, P. J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0777 · Cited by 63
Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma
Lamoureux, F., Picarda, G. G. A., Garrigue‐Antar, L., Baud’huin, M., Trichet, V., Vidal, A., Miot-Noirault, E., Pitard, B., Heymann, D., & Rédiní, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2648 · Cited by 59
Self-citationHeymann, M., Hérisson, F., Davaine, J., Charrier, C., Battaglia, S., Passuti, N., Lambert, G. C., Gouëffic, Y., & Heymann, D. (2012) · Cytokine · doi:10.1016/j.cyto.2012.02.004 · Cited by 55
Self-citationProteases and bone remodelling
Georges, S., Velasco, C. R., Trichet, V., Fortun, Y., Heymann, D., & Padrines, M. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.005 · Cited by 52
Self-citationHelske, S., Kovanen, P. T., Lindstedt, K. A., Salmela, K. T., Lommi, J., Turto, H., Werkkala, K., & Kupari, M. M. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2006.10.015 · Cited by 47
Ware, C. F. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.05.001 · Cited by 46
Role of αv integrin in osteoprotegerin-induced endothelial cell migration and proliferation
Kobayashi‐Sakamoto, M., Isogai, E., Hirose, K., & Chiba, I. (2008) · Microvascular Research · doi:10.1016/j.mvr.2008.06.004 · Cited by 45
Direct anti‐cancer effect of oncostatin M on chondrosarcoma
David, E., Guihard, P. J., Royer, B. B.-L., Riet, A., Charrier, C., Battaglia, S., Gouin, F., Ponsolle, S., Bot, R. L., Richards, C. D., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25776 · Cited by 43
Self-citationRegulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment
Lamoureux, F., Moriceau, G., Picarda, G. G. A., Rousseau, J., Trichet, V., & Rédiní, F. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.004 · Cited by 43
Self-citationRoyer, B. B.-L., Chipoy, C., Mori, K., Charrier, C., Battaglia, S., Pilet, P., Richards, C. D., Heymann, D., Rédiní, F., & Blanchard, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4781 · Cited by 40
Self-citationAnti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences
Heymann, D. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.03.001 · Cited by 36
Self-citationEffects of a sulfated exopolysaccharide produced by Altermonas infernus on bone biology
Velasco, C. R., Baud’huin, M., Sinquin, C., Maillasson, M., Heymann, D., Colliec‐Jouault, S., & Padrines, M. (2011) · Glycobiology · doi:10.1093/glycob/cwr002 · Cited by 35
Self-citationMechanistic study of the proangiogenic effect of osteoprotegerin
Benslimane-Ahmim, Z., Poirier, F., Deloménie, C., Lokajczyk, A., Grelac, F., Galy–Fauroux, I., Mohamedi, A., Fischer, A., Heymann, D., Lutomski, D., et al. (2013) · Angiogenesis · doi:10.1007/s10456-013-9337-x · Cited by 33
Self-citationInteraction of Heparins with Fibroblast Growth Factors: Conformational Aspects
Guerrini, M., Hricovı́ni, M., & Torri, G. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781039733 · Cited by 32
OPG, RANK and RANK ligand expression in thyroid lesions
Heymann, M., Riet, A., Goff, B. L., Battaglia, S., PAINEAU, J., & Heymann, D. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.02.004 · Cited by 30
Self-citationBaud’huin, M., Ruiz-Velasco, C., Jégo, G., Charrier, C., Gasiunas, N., Gallagher, J. T., Maillasson, M., Naggi, A., Padrines, M., Rédiní, F., et al. (2010) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.08.001 · Cited by 27
Self-citationChollet, M. E., Brouland, J., Sollier, C. B. D., Bauduer, F., Drouet, L. O., & Bellucci, S. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07989.x · Cited by 27
Picarda, G. G. A., Trichet, V., Télétchéa, S., Heymann, D., & Rédiní, F. (2012) · Europe PMC (PubMed Central) · Cited by 26
Self-citationKobayashi‐Sakamoto, M., Hirose, K., Nishikata, M., Isogai, E., & Chiba, I. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00458.x · Cited by 24
Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S. J., Ponomarev, V., Diamond, P., Findlay, D. M., Zannettino, A. C. W., & Evdokiou, A. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.244 · Cited by 21
Adachi, T., Matsushita, T., Dong, Z., Katsumi, A., Nakayama, T., Kojima, T., Saito, H., Sadler, J. E., & Naoe, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.126 · Cited by 21
Chikatsu, N., TAKEUCHI, Y., Fukumoto, S., Yano, K., Fujita, N., Tsuruo, T., & Fujita, T. (2002) · Endocrine Journal · doi:10.1507/endocrj.49.439 · Cited by 19
Yongchaitrakul, T., Manokawinchoke, J., & Pavasant, P. (2009) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2008.01190.x · Cited by 8
Fleishman, D. G., Gambaryan, S. P., Lavrora, E. A., Nikiforov, V. A., Saulus, A. A., & Vasilieva, V. F. (1990) · PubMed · Cited by 5
PL6.2. Bone cell–tumor cell interactions in prostate cancer
Corey, E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.020 · Cited by 1
Lamoureux, F., Picarda, G. G. A., Trichet, V., Pitard, B., Heymann, D., & Rédiní, F. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.104 · Cited by 1
Self-citation
Cited by
Sorted by citations
Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599
Tumor-related interleukins: old validated targets for new anti-cancer drug development
Setrerrahmane, S., & Xu, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0721-9 · Cited by 245
The Great Beauty of the osteoclast
Cappariello, A., Maurizi, A., Veeriah, V., & Teti, A. M. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.017 · Cited by 203
Salivary cytokines as biomarkers of periodontal diseases
Jaedicke, K. M., Preshaw, P. M., & Taylor, J. J. (2015) · Periodontology 2000 · doi:10.1111/prd.12117 · Cited by 172
RANK–RANKL signalling in cancer
Renema, N., Navet, B., Heymann, M., Lézot, F., & Heymann, D. (2016) · Bioscience Reports · doi:10.1042/bsr20160150 · Cited by 171
Self-citation
Metadata
- Authors
- Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D.
- Affiliations
- Inserm (FR)
- Université de Bourgogne (FR)
- Corresponding author
- Baud’huin, Marc
- Heymann, Dominique
- ORCID
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 24
- Issue
- 5
- Pages
- 401-409
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W2032215600
- Cited by
- 153
- References
- 85
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 14 · 2023: 14 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 12 · 2018: 8 · 2017: 10 · 2016: 21 · 2015: 16 · 2014: 9 · 2013: 1
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cytokine & Growth Factor Reviews (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
- Keywords
- osteoprotegerin, RANKL, TRAIL, glycosaminoglycans, proteoglycans, osteoclastogenesis, bone turnover, cell survival, cell proliferation, cell migration, vascular biology, tumor biology
- MeSH terms
- Animals, Cell Differentiation, Cell Survival, Humans, Osteoclasts, Cell Proliferation, TNF-Related Apoptosis-Inducing Ligand, Osteoprotegerin, RANK Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
